Serodus licenses compound from Roche for potential treatment of heart failure

9 December 2010 - Serodus has entered into a license agreement with Roche for a selective serotonin-4 (5-HT4) antagonist for the potential treatment of heart failure (RO1160367). Under the Agreement, Serodus will receive the full preclinical and clinical documentation for RO1160637. In return, Roche will receive an upfront payment as well as be entitled to receive development, regulatory and commercial milestone payments. Roche is also eligible to receive royalties on sales of products commercialized under the license. Serodus has been granted the exclusive development, manufacturing and worldwide marketing and sale rights with the rights to sub-license.


In certain cases, Roche has a right to negotiate to regain the product rights... Serodus' Press Release -

Micell Technologies : First Patient in DESSOLVE I First-In-Human Study of MiStent DES

November 29, 2010- MiStent DES Delivers Sirolimus via Bioabsorbable Polymer; Drug and Polymer are Designed to be Eliminated within 90 days with Optimized Dissolution Kinetics - Micell Technologies,™ Inc. announced it has enrolled at Mercy Hospital in Auckland, New Zealand, the first patient in DESSOLVE I (DES with Sirolimus and a bioabsorbable pOLymer for the treatment of patients with de noVo lEsions in the native coronary arteries), a first-in-human clinical trial of the company’s investigational MiStent™ Drug Eluting Coronary Stent System (MiStent DES).

DESSOLVE I is a prospective, open-label, non-randomized, single-arm study that is expected to enroll 30 patients at five clinical sites in Belgium, Australia and New Zealand. Candidates for the trial are patients with documented stable or unstable angina pectoris or ischemia. The primary endpoint is in-stent late lumen loss, as measured with angiography in treated de novo lesions ranging in diameter from 2.5 to 3.5 mm and amenable to treatment with a maximum 23 mm long stent.

Along with secondary clinical endpoints such as major adverse cardiac events and revascularization rates, intravascular ultrasound (IVUS) and optical coherence tomography (OCT) will also be employed at multiple timepoints. The DESSOLVE I study uses multiple imaging modalities to better understand the time to complete tissue coverage of the stent struts relative to polymer absorption... [PDF] Micell Technologies' Press Release -